Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Michael B. Atkins

ResearcherPublications, citations & collaboration network
1,066
Works
95,579
Citations
122
h-index
464
i10-index
How has Michael B. Atkins's publication output changed over time?
ScholarIQpublication output · 2012–2019

Output grew0% over the shown period — from 1 works in 2012 to 1 in 2019.

1
1
1
1
1
20122014201720182019
What are the most-cited papers on Michael B. Atkins?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,716 CitationsOPEN ACCESS
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Journal of Clinical Oncology. 20183,719 CitationsOPEN ACCESS
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Robert D. Hawkins, Dmitry Nosov, Frédéric Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Yen‐Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles
New England Journal of Medicine. 20193,428 CitationsOPEN ACCESS
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto
New England Journal of Medicine. 20172,214 CitationsOPEN ACCESS
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atkins, John D. Powderly, Philip D. Leming, Evan J. Lipson, Igor Puzanov, David C. Smith, Janis M. Taube, Jon M. Wigginton, Georgia Kollia, Ashok Gupta, Drew M. Pardoll, Jeffrey A. Sosman, F. Stephen Hodi
Journal of Clinical Oncology. 20142,212 Citations
Related on ScholarIQ
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Paper
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Paper
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Paper
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Paper
Immunotherapy and Immune Responses
Topic
470M+ articles · free account